ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

ATE Antibe Therapeutics Inc

0.295
0.00 (0.00%)
04 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Antibe Therapeutics Inc ATE Toronto Common Stock
  Price Change Price Change % Share Price Last Trade
0.00 0.00% 0.295 10:00:00
Open Price Low Price High Price Close Price Previous Close
0.295
more quote information »

Recent News

Date Time Source Heading
25/4/202401:15BWAntibe Announces Appointment of Receiver
19/4/202422:00BWAntibe Provides Update on CCAA Proceedings
17/4/202407:00BWAntibe Announces TSX Delisting Review
10/4/202409:00BWAntibe Announces Granting of Initial Order Under Companies'..
10/4/202401:25PRNCACanadian Investment Regulatory Organization Trade Resumption..
09/4/202423:44PRNCASuspension de la négociation par l'Organisme canadien de..
09/4/202423:42PRNCACanadian Investment Regulatory Organization Trading Halt -..
09/4/202421:00BWAntibe to File an Application for an Initial Order Under..
01/4/202422:00BWAntibe Announces FDA Clinical Hold on Otenaproxesul and..
20/3/202422:00BWAntibe to Present Otenaproxesul PK/PD Results at the ASRA..
07/3/202423:00BWAntibe to Present Otenaproxesul PK/PD Results at the..
04/3/202423:00BWAntibe Announces Unfavorable Decision in Arbitration With..
14/2/202423:00BWAntibe Reports Q3 2024 Interim Financial and Operating..
01/2/202423:00BWAntibe Extends Early Warrant Exercise Incentive Program
29/12/202323:00BWAntibe Announces Early Warrant Exercise Incentive Program
12/12/202323:00BWAntibe Therapeutics Announces Amendment to Warrant Terms
13/11/202323:00BWAntibe Reports Q2 2024 Interim Financial and Operating..
09/11/202323:00BWAntibe Reports PK Results of First Clinical Study of..
01/11/202322:00BWAntibe Completes First Clinical Study of Otenaproxesul’s New..
18/10/202322:00BWAntibe Initiates First Clinical Study of Otenaproxesul’s New..
28/9/202321:00BWAntibe Receives Approval to Initiate PK/PD Study of..
09/9/202307:00BWAntibe Announces Results of 2023 Annual Meeting
22/8/202305:23PRNCAToronto Stock Exchange, Antibe Therapeutics Inc., View From..
14/8/202321:00BWAntibe Reports Q1 2024 Interim Financial and Operating..
29/6/202321:30BWAntibe Reports 2023 Year-End Results and Business Highlights

Your Recent History

Delayed Upgrade Clock